[SCHEDULE 13G/A] Forte Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Alger Associates, Inc. reports beneficial ownership of 1,618,649 shares of Forte Biosciences common stock, representing 13.3% of the class. Alger discloses sole voting power over 1,608,040 shares and sole dispositive power over 1,618,649 shares. The securities are held for one or more open-end investment companies or managed accounts advised by Fred Alger Management, LLC, a wholly owned subsidiary of Alger Group Holdings, LLC, which in turn is owned by Alger Associates, Inc. The filing indicates these holdings are held in the ordinary course of business and not for the purpose of changing or influencing control.

Positive

• Material disclosure of a 13.3% beneficial stake, improving transparency for investors
• Sole voting and dispositive power stated for the reported shares, clarifying control rights

Negative

• None.

Insights

Financial Analyst

TL;DR: Alger holds a material, passive stake of 13.3% in Forte Biosciences with near-total sole voting and dispositive power over those shares.

Alger's 13.3% position is large enough to be investor-significant but the Schedule 13G format and the certification state the stake is held in the ordinary course of business and not to influence control. Ownership is through investment vehicles managed by Fred Alger Management, LLC, indicating portfolio exposure rather than an activist intent. For investors, this identifies a concentrated institutional holder whose trading could affect free float and liquidity, but the filing contains no indication of change-in-control activities.

Corporate Governance Expert

TL;DR: A 13.3% holder with sole voting power is notable for governance monitoring but the filer attests to passive intent.

From a governance perspective, sole voting power over 1,608,040 shares means Alger can influence votes if it chooses, yet the Schedule 13G classification and signature statement affirm passive ownership. The disclosure of the ownership chain—Alger Associates, Alger Group Holdings and Fred Alger Management—provides clear stewardship lines. No other governance actions, board nominations or group affiliations are disclosed in this filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

Forte Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

34962G208

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 34962G208

1

Names of Reporting Persons

Alger Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,608,040.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,618,649.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,618,649.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.3 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Forte Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 3060 Pegasus Park Drive, Building 6, Dallas, TX 75247
Item 2.
(a)	Name of person filing: Alger Associates, Inc.
(b)	Address or principal business office or, if none, residence: 100 Pearl Street, 27th Floor, New York, NY 10004
(c)	Citizenship: New York
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 34962G208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,618,649
(b)	Percent of class: 13.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,608,040
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,618,649
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC ("FAM"), a registered investment adviser. FAM is a 100% owned subsidiary of Alger Group Holdings, LLC ("AGH"), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit A.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alger Associates, Inc.

Signature:	/s/ Hal Liebes
Name/Title:	Hal Liebes / Secretary
Date:	08/14/2025

FAQ

How many Forte Biosciences (FBRX) shares does Alger Associates own?

Alger Associates reports beneficial ownership of 1,618,649 shares, representing 13.3% of the class.

Does Alger Associates have voting power over its FBRX shares?

Yes. The filing reports sole voting power for 1,608,040 shares and sole dispositive power for 1,618,649 shares.

Are the FBRX shares held on behalf of clients or the firm?

The securities are held by open-end investment companies or managed accounts that are clients of Fred Alger Management, LLC, an investment adviser and subsidiary within the Alger ownership chain.

Is Alger Associates seeking to influence control of Forte Biosciences?

The signer certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

How is the Alger ownership structure described in the filing?

Fred Alger Management, LLC is a 100% owned subsidiary of Alger Group Holdings, LLC, which is a 100% owned subsidiary of Alger Associates, Inc., per the filing.